Skip to main content
Kathryn Cappell, MD, Oncology, Fairfax, VA, Suburban Hospital

KathrynMarieCappellMDPHD

Oncology • Fairfax, VA

Hematologic Oncology

Hematology/Oncology Physician at the National Cancer Institute

Join to view full profile

Dr. Cappell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Cappell's full profile

Already have an account?

Summary

  • I began my medical training at UNC-Chapel Hill where I completed a combined Medical Science Training Program (MSTP) MD/PhD degree. My research for my PhD was in the area of cancer pharmacology identifying modulators of chemosensitivity to paclitaxel. The time I spent performing research generated two first author publications, multiple middle author publications, and gave me experience in generating and testing research hypotheses. During my PhD training, I developed an interest in the development of oncology therapeutics and I therefore completed my medical training with the goal of specializing in hematology and oncology. I completed my residency training in internal medicine at Stanford University followed by a fellowship in blood and marrow transplantation at Stanford University. I then completed my training in hematology/oncology at the National Cancer Institute (NCI). At the NCI, my research has focused on the development of chimeric antigen receptor T cells (CAR T) cells for lymphoma. My recent work in this area was highlighted at the American Society of Clinical Oncology (ASCO) 2020 conference in a poster discussion session. I have also been recognized for my strong work at the NCI by being named associate chief fellow in 2019-2020, earning the Herb Kotz Exemplary Oncologist award, and an ASCO endowed merit award in 2020.

Clinical Expertise

  • Clinical protocols, Hematology, Drug development, Clinical research, Oncology

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2018 - 2021
  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2013 - 2016
  • University of North Carolina at Chapel Hill School of Medicine
    University of North Carolina at Chapel Hill School of MedicineClass of 2013

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2014 - Present
  • VA State Medical License
    VA State Medical License 2021 - 2026
  • MD State Medical License
    MD State Medical License 2017 - 2022
  • DC State Medical License
    DC State Medical License 2020 - 2022
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • American Society of Clinical Oncology Anthony and Marilyn Tolcher Endowed Merit Award 2020
  • Assistant chief fellow of the National Cancer Insititute 2019-2020
  • Herb Kotz Exemplary Oncologist Award National Cancer Institute, 2019
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Advance directive utilization is associated with less aggressive end-of-life care in patients undergoing allogeneic hematopoietic cell transplantation  
    Cappell K, Sundaram V, Park A, Shiraz P, Gupta R, Jenkins P, Periyakoil VSJ, Muffly, Biology of Blood and Marrow Transplantation, 2018
  • Mechanisms promoting escape from mitotic stress-induced tumor cell death  
    Sinnott R, Winters L, Larson B, Mytsa D, Taus P, Cappell KM, Whitehurst AW, Cancer Research, 2014
  • The 3M complex maintains microtubule and genome integrity  
    Yan J, Yan F, Li Z, Sinnott B, Cappell KM, Yu Y, Mo J, Duncan JA, Chen X, Cormier-Daire V, Whitehurst AW, Xiong Y, Molecular Cell, 2014

Abstracts/Posters

  • Long-term follow-up of anti-CD19 CAR T-cell therapy for B-cell lymphoma and chronic lymphocytic leukemia
    Cappell KM, Sherry RM, Yang JC, Goff SL, Vanasse D, McIntyre L, Rosenberg SA, Kochenderfer JN, American Society of Clinical Oncology Annual Conference, 5/2020

Press Mentions

  • Durable Remission, Rare Adverse Effects With Anti-CD19 CAR-T Therapy
    Durable Remission, Rare Adverse Effects With Anti-CD19 CAR-T TherapyJuly 10th, 2020
  • Axi-Cel Induces Durable Remissions in Relapsed CLL, B-Cell Lymphoma
    Axi-Cel Induces Durable Remissions in Relapsed CLL, B-Cell LymphomaJuly 10th, 2020
  • Durable Long-Term Responses in B-cell Lymphoma and Chronic Lymphocytic Leukemia After Anti-CD19 CAR T-Cell Therapy
    Durable Long-Term Responses in B-cell Lymphoma and Chronic Lymphocytic Leukemia After Anti-CD19 CAR T-Cell TherapyJuly 10th, 2020
  • Join now to see all

Professional Memberships

Hospital Affiliations

Dr. Kathryn Cappell, Dr. Kathryn Cappell, MD, Dr. K Cappell, Dr. Kathryn Marie Cappell